Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy TG Therapeutics stock

Own TG Therapeutics stock in just a few minutes.

TG Therapeutics, Inc is a biotechnology business based in the US. TG Therapeutics shares (TGTX) are listed on the NASDAQ and all prices are listed in US Dollars. TG Therapeutics employs 272 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in TG Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – TGTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

TG Therapeutics share price

Use our graph to track the performance of TGTX stocks over time.

TG Therapeutics shares at a glance

Information last updated 2021-04-23.
52-week range$10.83 - $56.74
50-day moving average $45.71
200-day moving average $41.37
Wall St. target price$73.14
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.96

Buy TG Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy TG Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

TG Therapeutics financials

Revenue TTM $152,000
Gross profit TTM $152,000
Return on assets TTM -43.36%
Return on equity TTM -100.14%
Profit margin 0%
Book value $4.00
Market capitalisation $5.9 billion

TTM: trailing 12 months

Shorting TG Therapeutics shares

There are currently 11.8 million TG Therapeutics shares held short by investors – that's known as TG Therapeutics's "short interest". This figure is 1.3% down from 12.0 million last month.

There are a few different ways that this level of interest in shorting TG Therapeutics shares can be evaluated.

TG Therapeutics's "short interest ratio" (SIR)

TG Therapeutics's "short interest ratio" (SIR) is the quantity of TG Therapeutics shares currently shorted divided by the average quantity of TG Therapeutics shares traded daily (recently around 1.5 million). TG Therapeutics's SIR currently stands at 7.76. In other words for every 100,000 TG Therapeutics shares traded daily on the market, roughly 7760 shares are currently held short.

However TG Therapeutics's short interest can also be evaluated against the total number of TG Therapeutics shares, or, against the total number of tradable TG Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case TG Therapeutics's short interest could be expressed as 0.08% of the outstanding shares (for every 100,000 TG Therapeutics shares in existence, roughly 80 shares are currently held short) or 0.1043% of the tradable shares (for every 100,000 tradable TG Therapeutics shares, roughly 104 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against TG Therapeutics.

Find out more about how you can short TG Therapeutics stock.

TG Therapeutics share dividends

We're not expecting TG Therapeutics to pay a dividend over the next 12 months.

Have TG Therapeutics's shares ever split?

TG Therapeutics's shares were split on a 100:5625 basis on 29 April 2012. So if you had owned 5625 shares the day before before the split, the next day you'd have owned 100 shares. This wouldn't directly have changed the overall worth of your TG Therapeutics shares – just the quantity. However, indirectly, the new 5525% higher share price could have impacted the market appetite for TG Therapeutics shares which in turn could have impacted TG Therapeutics's share price.

TG Therapeutics share price volatility

Over the last 12 months, TG Therapeutics's shares have ranged in value from as little as $10.83 up to $56.74. A popular way to gauge a stock's volatility is its "beta".

TGTX.US volatility(beta: 2.2)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while TG Therapeutics's is 2.2013. This would suggest that TG Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

TG Therapeutics overview

TG Therapeutics, Inc. , a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7. 1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc. , Jiangsu Hengrui Medicine Co.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site